Dr.Miloš Holánek (Clinical oncologist)– Best Costs, Reviews – Book Your Consultation

Professional Experience

• Current Position: Consultant Medical Oncologist at the Comprehensive Cancer Care Department, MMCI.
• Clinical Focus: Specializes in the treatment of solid tumors, with a particular emphasis on breast cancer.
• Research Involvement: Actively participates in clinical trials and research projects aimed at improving cancer treatment outcomes.

Academic Contributions

• Teaching Role: Serves as an assistant professor at Masaryk University, educating medical students and residents in oncology.
• Ph.D. Supervision: Supervises Ph.D. candidates in the field of oncology and hematology, guiding research projects and dissertations.
• Research Projects: Involved in various research initiatives focusing on the improvement of cancer care and treatment methodologies.

Areas of Expertise

• Solid Tumors: Expertise in the diagnosis and treatment of various solid tumors, including breast cancer.
• Breast Cancer: Specializes in the management of breast cancer, encompassing neoadjuvant chemotherapy, surgical interventions, and post-treatment care.
• Clinical Trials: Participation in clinical trials to evaluate new treatment modalities and improve patient outcomes.

Publications and Research

Dr. Holánek has contributed to several peer-reviewed publications in the field of oncology. Notable works include:

• Primary Breast Sarcoma: A Two-Centre Analysis and Review of Literature – A comprehensive study on primary breast sarcoma, published in Breast Care (Basel), August 2023. This research provides valuable insights into the clinical management and outcomes of primary breast sarcoma patients.
• Impact of Breast Cancer Neoadjuvant Chemotherapy on Plasma and Urine Amino Acid Profile, Plasma Proteins, and Nitrogen Metabolism – Published in 2024, this study explores the metabolic changes induced by neoadjuvant chemotherapy in breast cancer patients, offering potential biomarkers for treatment response.
• Axillary Overtreatment in Patients with Breast Cancer After Neoadjuvant Chemotherapy in the Current Era of Targeted Axillary Dissection – A 2025 publication addressing the issue of axillary overtreatment in breast cancer patients post-neoadjuvant chemotherapy, emphasizing the role of targeted axillary dissection in treatment planning.

Patient Care Philosophy

Dr. Holánek is committed to providing compassionate and personalized care to oncology patients. He emphasizes:

• Patient-Centered Approach: Prioritizing patient preferences and values in treatment decisions.
• Multidisciplinary Collaboration: Working closely with a team of specialists to develop comprehensive treatment plans.
• Patient Education: Ensuring patients are well-informed about their condition and treatment options to make empowered decisions.

Professional Affiliations

• Masaryk University: Faculty member in the Department of Comprehensive Cancer Care.
• Masaryk Memorial Cancer Institute: Consultant Medical Oncologist, contributing to clinical and research initiatives.
• European Society for Medical Oncology (ESMO): Member, staying abreast of the latest developments in oncology.
• Czech Society of Oncology: Active participant in national oncology conferences and workshops.

FAQs

Is Dr. Holánek board-certified?

Yes, Dr. Holánek is board-certified in medical oncology and holds a Ph.D. in oncology.

What types of cancers does he treat?

Dr. Holánek specializes in the treatment of solid tumors, with a particular focus on breast cancer.

Does he treat international patients?

Yes, MMCI provides services to international patients, and Dr. Holánek is involved in their care.

How long is the typical hospital stay?

The length of hospital stay varies depending on the treatment plan and individual patient needs.

What languages does Dr. Holánek speak?

Dr. Holánek is proficient in Czech and English, facilitating communication with a broad patient demographic.